Roche discontinues depression agent
This article was originally published in Pharmaceutical Approvals Monthly
Roche discontinues development of its neurokinin-1 antagonist R-673 for depression due to difficulties distinguishing between placebo and treatment arms in two Phase II trials, the firm says July 20 during its second quarter earnings call. The Phase II data "showed we couldn't get below a 50% response rate with placebo," Pharmaceutical Division CEO William Burns explained. Roche said it is open to outlicensing the agent. Other firms developing neurokinin antagonists include GlaxoSmithKline and Sanofi-Aventis...
You may also be interested in...
Japanese medical device manufacturer Terumo Corp. promoted senior management execs; MiMedx Group, developer of human placental tissue allografts, raised exec to CFO; and more.
COVID-19: String Of FDA Guidance Docs Lay Bare Enforcement Policies For Infusion Pumps, ECMO Devices, Thermometers, And More
In three separate immediately-in-effect guidance documents, the US agency says makers of infusion pumps and accessories, extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass devices, and remote ophthalmic assessment and monitoring devices can make “limited modifications” to those products so they can be used during the ongoing novel coronavirus crisis, without the need for firms to seek out a new 510(k). A fourth guidance says clinical electronic thermometers that aren’t yet 510(k)-cleared by the FDA can be distributed for use.
Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.